Duloxetine in Inflammatory Bowel Diseases

Exclusion Criteria

• •Concomitant use of antidepressants (including serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, tricyclic antidepressants, buspirone, and thioridazine).
• •Initiation of psychotherapy within 8 weeks.
• •Inability or unwillingness to monitor ambulatory blood pressure and receive a blood pressure monitor via postal mail.
• •Cirrhosis with clinically evident hepatic insufficiency (Child-Pugh Class B or C) by medical record review.1
• •Severe renal impairment (on dialysis; chronic kidney disease stage 4-5; acute kidney injury with glomerular filtration rate \<30 mL/minute) by medical record review of labs performed within 18 months.
• •Concurrent participation in another clinical trial of an investigational medicinal product.
• •Pregnant or lactating either by self-report or medical record review
• •Glaucoma
• •Gastroparesis
• •Use of medications that could lead to serious interactions with the study medication: potent CYP1A2 inhibitors, antidepressants (including serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, buspirone, thioridazine), linezolid, intravenous methylene blue, triptans, lithium, fentanyl, tramadol, meperidine, methadone, tryptophan, amphetamines, and St. John's Wort.
• •Bipolar, psychotic, alcohol use disorder, non-alcohol substance-induced disorders, or imminent danger to self or others